Correlation between TEM1 expression and efficacy of neoadjuvant chemotherapy in patients with gastric cancer
10.3969/j.issn.1000-8179.2019.04.353
- VernacularTitle:TEM1表达与胃癌患者新辅助化疗疗效相关性研究*
- Author:
Junxia TANG
1
;
Ziying DAI
;
Tingting PAN
;
Yonglin CHEN
;
Yongning ZHOU
;
Quanlin GUAN
Author Information
1. 兰州大学第一临床医学院(兰州市730000)
- Keywords:
gastric cancer;
neoadjuvant chemotherapy;
tumor endothelial marker 1 (TEM1);
sensitivity;
predictive index
- From:
Chinese Journal of Clinical Oncology
2019;46(4):173-177
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To detect the expression of P53, human epidermal growth factor receptor-2 (HER-2), and tumor endothelial marker 1 (TEM1) in gastric cancer tissues, analyze their correlation with clinical efficacy, and explore their potential roles as biomarkers for neoadjuvant chemotherapy. Methods: Sixty-three patients with gastric cancer who underwent fluorouracil-based neoadjuvant che-motherapy in The First Hospital of Lanzhou University from May 2015 to May 2017 were enrolled. Using immunohistochemistry, the expression of P53, Her2, and TEM1 was detected in 63 gastric cancer specimens before neoadjuvant chemotherapy. The efficacy of neoadjuvant chemotherapy was assessed by imaging. The relationship between the expression of P53, HER-2, and TEM1 and the effi-cacy of neoadjuvant chemotherapy was analyzed. Results: The total effective rate of neoadjuvant chemotherapy in 63 patients with advanced gastric cancer was 69.8%, with 2, 7, and 35 patients achieving complete remission, partial remission, and stable disease, re-spectively. Disease progression was noted in 19 patients. Univariate analysis revealed that patients positive for TEM1 and having high T stage had a poor response to neoadjuvant chemotherapy (P<0.05); furthermore, location, differentiation, and size of tumor; P53 posi-tivity (P=0.488); and Her-2 positivity (P=0.106) were not associated with the efficacy of neoadjuvant chemotherapy for gastric cancer. Multivariate analysis revealed that TEM1 positivity and a higher T stage could be factors that predicted the response to neoadjuvant chemotherapy in patients with advanced gastric cancer. Conclusions: TEM1, as a marker of tumor stroma, may be an important molec-ular biological indicator that predicts the poor response to neoadjuvant chemotherapy in patients with gastric cancer.
